Type 1 Diabetes and SGLT2 Inhibitors - Children with Diabetes
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
SGLT2 Inhibitors for Teens With Type 1 Diabetes
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/figure1-potential-mechanisms-for-sodium-glucose.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
FDA weighs risks of new treatment for type 1 diabetes - Diabetes Voice
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/table1-minimizing-the-risk-of-diabetic.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
Insulin Therapy in Combination With SGLT2 Inhibitors in Type 1 and Type... | Download Table
Orale Begleittherapien bei Typ-1-Diabetes – die Nutzen und Risiken
Could SGLT2 Inhibitors Be Part of a New Treatment for Type 1 Diabetes? – BETTER
Type 1 diabetes could begin in the womb, new research suggests – Diabetologia
EMA hält SGLT2-Inhibitor auch bei Typ-1-Diabetes für geeignet
Summary of evidence for SGLT-2 inhibitors in type 1 diabetes | Download Table
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis | Scientific Reports
Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study) - Media Centre | EASD
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials - The Lancet Diabetes & Endocrinology
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
News
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature | Bentham Science
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
SGLT2 Inhibitors in Type 1 Diabetes: Friend or Foe? - Taking Control Of Your Diabetes®
Typ-1-Diabetes
Cureus | Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
